Deals channel feed – Endpoints News

Deals channel feed

With sparse R&D prospects, Incyte bets $900M on MorphoSys' CAR-T rival tafasitamab

6 years ago

Merck-partnered biotech hands Roche its half-life extension tech as it pivots to immuno-oncology

6 years ago

Eli Lilly buys a Roche discard in $1.1B Dermira buyout. Can they go toe-to-toe with the heavyweight challenger Dupixent?

6 years ago

Ionis finds new partner in a young biotech and its hopeful founder

6 years ago

Eyeing the 'translatome,' Pfizer ties another knot with biotech partner for preclinical, next-gen targeted therapies

6 years ago

Boehringer Ingelheim inks 'Singapore's largest biotech deal,' promising $1B each for a suite of anti-fibrotic IL-11 drugs

6 years ago

Just how big is the biopharma dealmaking world? In 2019 we saw megabillions in cash change hands, and that's just the tip of the iceberg

6 years ago

AstraZeneca gets in on RNA game with MiNA research collaboration

6 years ago

Merck dives deeper into KRAS, teaming up with Taiho, Astex to develop small molecule drugs

6 years ago

Illumina's $1.2B buyout dies amid FTC 'monopolist' accusation

6 years ago

Sanofi's hurried, $2.5B pursuit for Synthorx drove buyout price high and left keen rival sorely disappointed

6 years ago

Over a decade into the milestone boom, it's time to ask. Just how often do they really pay off?

6 years ago

J&J rounds out the year with twin buyouts, gaining control of delivery and surgical robotics tech

6 years ago

Sarepta cements its DMD throne with $1B+ gene therapy deal with mighty Roche

6 years ago

Biogen makes cautious bet on dry AMD as partner Catalyst Bio moves anti-C3 drug toward the clinic

6 years ago

Novartis elects to keep one heart drug, discard the other from option deal with Akcea, Ionis

6 years ago

Deerfield adds Duke to its roster of college partners, kicking off a $130M discovery alliance

6 years ago

FTC calls out Illumina as 'monopolist,' moves to block $1.2B acquisition of PacBio

6 years ago

Inside Astellas' $3B Audentes gene therapy acquisition: coded messages, a bidding war and $77M for the CEO

6 years ago

UK antitrust watchdog clears Roche/Spark deal — but what is the FTC thinking?

6 years ago

Battered, cash hungry Intec feels the burn of Novartis rejection

6 years ago

AbbVie, Scripps expand partnership, fortify focus on cancer drugs

6 years ago

In a play-by-play of the $9.7B MedCo buyout, Novartis admits it overpaid while offering a huge windfall to execs

6 years ago

New Sanofi CEO Hudson adds next-gen cancer drug tech to the R&D quest, buying Synthorx for $2.5B

6 years ago

First page Previous page 95 96 979899 100 101 Next page Last page